Back to Journals » Journal of Inflammation Research » Volume 13

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Authors Reddy V, Yang EJ, Myers B, Liao W

Received 27 November 2019

Accepted for publication 7 January 2020

Published 22 January 2020 Volume 2020:13 Pages 53—60


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Ning Quan

Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1

1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USA

Correspondence: Vidhatha Reddy
UCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA 94118, USA
Tel +1 661-340-3418

Abstract: Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.

Keywords: risankizumab, plaque psoriasis, IL-23 inhibitor, biologics, safety, efficacy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]